Recursion Pharmaceuticals is laying off a fifth of its workforce in connect with a previously announced streamlining of the AI biotech’s pipeline.

Shares of Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to ...

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning ...

Recursion Pharmaceuticals stock isn't a good fit for risk-averse investors. The company remains unprofitable and is losing more money as it ramps up clinical development of several candidates.

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc.

Salt Lake City-based Recursion Pharmaceuticals said on Feb. 19, 2025 it was introducing a pre-seed investment fund in response to the federal government slashing costs at the National Institutes ...

If policymakers fail to act swiftly to restore medical research funding, then it’s up to those of us in the industry with the resources to bridge the gap, writes Recursion Pharmaceuticals CEO ...

Najat Khan, PhD, Recursion Pharmaceuticals chief R&D officer and chief commercial officer With at least seven of its programs expected to begin human trials or read out clinical data during 2025 ...

Recursive Destruction in Marvel Rivals is a new mechanic that lets players rebuild specific structures during gameplay.

Nvidia-backed Recursion Pharmaceuticals said on Tuesday its experimental drug to treat a rare brain-related condition was safe and tolerable in a mid-stage study, but showed mixed results for ...

RXRX expects several data readouts throughout 2024 and 2025. Recursion’s oncology candidate, REC-994, is being evaluated in the mid-stage SYCAMORE study to treat cerebral cavernous malformation.